Nonalcoholic fatty liver disease burden – Switzerland 2018–2030
Nicolas Goossens(University Hospital of Geneva), Chris Estes(Center for Disease Analysis), François R. Jornayvaz(University of Geneva), Homie Razavi(Center for Disease Analysis), Stefano Bellentani(Ospedale Regionale di Locarno), David Semela(Kantonsspital St. Gallen), Andreas Cerny(Epatocentro Ticino), Joachim C. Mertens(GastroZentrum Hirslanden Zürich), Jean‐François Dufour(Universidad Iberoamericana), Alberto Moriggia(University of Zurich), Beat Muellhaupt, Francesco Negro(University Hospital of Geneva)
Cited by 24
Related Papers
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
|Hepatology|2017|2.4k
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
|The Lancet. Gastroenterology & hepatology|2016|2k
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030
|Journal of Hepatology|2018|2k
Global epidemiology and genotype distribution of the hepatitis C virus infection
|Journal of Hepatology|2014|1.9k